Frank, Rimerman Advisors LLC Alnylam Pharmaceuticals, Inc. Transaction History
Frank, Rimerman Advisors LLC
- $1.46 Billion
- Q2 2025
A detailed history of Frank, Rimerman Advisors LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Frank, Rimerman Advisors LLC holds 1,227 shares of ALNY stock, worth $590,272. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,227Holding current value
$590,272% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
763Shares Held
115MCall Options Held
584KPut Options Held
661K-
Capital World Investors Los Angeles, CA16.8MShares$8.08 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$6.4 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.59 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.46 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$2.06 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $59.2B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...